Cargando…
Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus
BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METH...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033120/ https://www.ncbi.nlm.nih.gov/pubmed/23644670 http://dx.doi.org/10.1136/annrheumdis-2012-203028 |
_version_ | 1782317766934528000 |
---|---|
author | Parker, Ben Al-Husain, Awal Pemberton, Philip Yates, Allen P Ho, Pauline Gorodkin, Rachel Teh, Lee Suan Alexander, M Yvonne Bruce, Ian N |
author_facet | Parker, Ben Al-Husain, Awal Pemberton, Philip Yates, Allen P Ho, Pauline Gorodkin, Rachel Teh, Lee Suan Alexander, M Yvonne Bruce, Ian N |
author_sort | Parker, Ben |
collection | PubMed |
description | BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METHODS: Twenty-seven patients with active SLE (four or more American College of Rheumatology (ACR) criteria) and 22 age-matched controls were assessed. Endothelial microparticles (EMPs; CD31+/annexin V+/CD42b−) were quantified using flow cytometry. Brachial artery flow-mediated dilatation (FMD) was measured using automated edge-tracking software. Twenty-two patients had a second assessment at a median (IQR) of 20 (16, 22) weeks after initiating new immunosuppressive therapy. RESULTS: SLE patients had a median (IQR) baseline global British Isles Lupus Assessment Group Disease Activity Index (BILAG-2004) score of 14 (12, 22). CD31+/annexin V+/CD42b− EMPs were higher (157 548/ml (59 906, 272 643) vs 41 025(30 179, 98 082); p=0.003) and endothelial-dependent FMD was lower (1.63% (−1.22, 5.32) vs 5.40% (3.02, 8.57); p=0.05) in SLE patients than controls. CD31+/annexin V+/CD42b− EMPs correlated inversely with FMD (%) (r(2) −0.40; p=0.006). At follow-up, the median (IQR) change in global BILAG-2004 score was −11 (−18, −3). CD31+/annexin V+/CD42b− EMP levels were reduced (166 982/ml (59 906, 278 775 vs 55 655(29 475, 188 659; p=0.02) and FMD had improved (0.33% (−2.31, 4.1) vs 3.19% (0.98, 5.09); p=0.1) at the second visit. CONCLUSIONS: Active SLE is associated with evidence of increased endothelial damage and endothelial dysfunction, which improved with suppression of inflammation. Better control of active inflammatory disease may contribute to improved cardiovascular risk in patients with SLE. |
format | Online Article Text |
id | pubmed-4033120 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-40331202014-06-05 Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus Parker, Ben Al-Husain, Awal Pemberton, Philip Yates, Allen P Ho, Pauline Gorodkin, Rachel Teh, Lee Suan Alexander, M Yvonne Bruce, Ian N Ann Rheum Dis Clinical and Epidemiological Research BACKGROUND: In a prospective observational study, we investigated whether patients with active systemic lupus erythematosus (SLE) had higher indices of endothelial damage and dysfunction than healthy controls and whether improved disease control was associated with improvement in these indices. METHODS: Twenty-seven patients with active SLE (four or more American College of Rheumatology (ACR) criteria) and 22 age-matched controls were assessed. Endothelial microparticles (EMPs; CD31+/annexin V+/CD42b−) were quantified using flow cytometry. Brachial artery flow-mediated dilatation (FMD) was measured using automated edge-tracking software. Twenty-two patients had a second assessment at a median (IQR) of 20 (16, 22) weeks after initiating new immunosuppressive therapy. RESULTS: SLE patients had a median (IQR) baseline global British Isles Lupus Assessment Group Disease Activity Index (BILAG-2004) score of 14 (12, 22). CD31+/annexin V+/CD42b− EMPs were higher (157 548/ml (59 906, 272 643) vs 41 025(30 179, 98 082); p=0.003) and endothelial-dependent FMD was lower (1.63% (−1.22, 5.32) vs 5.40% (3.02, 8.57); p=0.05) in SLE patients than controls. CD31+/annexin V+/CD42b− EMPs correlated inversely with FMD (%) (r(2) −0.40; p=0.006). At follow-up, the median (IQR) change in global BILAG-2004 score was −11 (−18, −3). CD31+/annexin V+/CD42b− EMP levels were reduced (166 982/ml (59 906, 278 775 vs 55 655(29 475, 188 659; p=0.02) and FMD had improved (0.33% (−2.31, 4.1) vs 3.19% (0.98, 5.09); p=0.1) at the second visit. CONCLUSIONS: Active SLE is associated with evidence of increased endothelial damage and endothelial dysfunction, which improved with suppression of inflammation. Better control of active inflammatory disease may contribute to improved cardiovascular risk in patients with SLE. BMJ Publishing Group 2014-06 2013-05-05 /pmc/articles/PMC4033120/ /pubmed/23644670 http://dx.doi.org/10.1136/annrheumdis-2012-203028 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Clinical and Epidemiological Research Parker, Ben Al-Husain, Awal Pemberton, Philip Yates, Allen P Ho, Pauline Gorodkin, Rachel Teh, Lee Suan Alexander, M Yvonne Bruce, Ian N Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title_full | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title_fullStr | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title_full_unstemmed | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title_short | Suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
title_sort | suppression of inflammation reduces endothelial microparticles in active systemic lupus erythematosus |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033120/ https://www.ncbi.nlm.nih.gov/pubmed/23644670 http://dx.doi.org/10.1136/annrheumdis-2012-203028 |
work_keys_str_mv | AT parkerben suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT alhusainawal suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT pembertonphilip suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT yatesallenp suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT hopauline suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT gorodkinrachel suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT tehleesuan suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT alexandermyvonne suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus AT bruceiann suppressionofinflammationreducesendothelialmicroparticlesinactivesystemiclupuserythematosus |